Colchicine, Clarithromycin, and a Kidney That Can't Absorb the Mistake
A single patient with a gout flare is also five days into clarithromycin for pneumonia, and has reduced kidney function on top of that. The disagreement is whether colchicine can be dosed carefully around that combination or has to be taken off the table entirely.
Victor A., a 57-year-old man, became a grandfather for the first time two weeks ago and has spent most evenings since on video calls trying to make out which of the baby's expressions his daughter insists look exactly like his. That routine was interrupted five days ago when a cough and fever sent him to urgent care, where he was diagnosed with community-acquired pneumonia and started on clarithromycin; he still works as an auto mechanic most days, though he'd already cut back to four days a week after his kidney function was flagged as declining last year. He arrives today with his right big toe swollen, red, and exquisitely tender — a classic podagra presentation, his second gout flare this year. His chronic kidney disease, attributed to twenty years of poorly controlled hypertension, has left him with a baseline creatinine around 2.2 and an eGFR of 34. His instinct, and his primary care physician's initial plan by phone, was to simply add his usual colchicine taper on top of the antibiotic he's already taking.
That instinct runs directly into one of the better-documented dangerous drug interactions in general medicine. Colchicine is cleared through a combination of CYP3A4 metabolism and P-glycoprotein-mediated transport, and clarithromycin potently inhibits both pathways at once — not a modest slowing of clearance but a compounding one, since the drug that would normally limit colchicine's absorption and speed its elimination is blocked on both fronts simultaneously. Hung and colleagues' case series of colchicine toxicity during clarithromycin co-administration documented deaths on this exact pairing, and the risk concentrates specifically in patients with reduced renal or hepatic function, since the kidney is colchicine's other major clearance route and an impaired kidney has no reserve capacity to compensate for the CYP3A4/P-gp blockade already underway. Victor's eGFR of 34 places him squarely inside that higher-risk group, not at its margin, and the fact that his declining renal function was only flagged last year — recent enough that no one has yet revisited his colchicine taper in light of it — is exactly the kind of gap this flare has now forced into the open.
A flare, an antibiotic, and a warning worth taking literally
This isn't a case for a reduced colchicine dose. The colchicine label specifically names strong CYP3A4/P-gp inhibitors combined with renal or hepatic impairment as a combination to avoid, and Hung's series documented fatal outcomes on exactly this pairing. His eGFR of 34 puts him squarely inside that higher-risk group, not near its edge. I'd treat that warning as close to a hard stop.
I agree the interaction is real, but he's two days from finishing a course that's already working — afebrile since day two, clinically improving. If simply withholding colchicine for those two days solves the interaction without touching his antibiotic, that seems like the path that protects both problems at once rather than forcing a choice between them.
I'd rather not switch or stop clarithromycin mid-course without a specific reason to — changing a working antibiotic regimen has its own real downside.
We don't actually need colchicine to treat this flare at all, which makes this simpler than it sounds. A short oral prednisone taper, or an intra-articular injection if he'd rather avoid systemic steroids, treats his gout just as effectively without going anywhere near the interaction. That solves it structurally — his antibiotic course stays untouched, and nobody has to manage around a warning this serious.
Skipping colchicine for two days would work, but it leaves him without active treatment for a flare that's genuinely painful right now — an alternative that treats him today is better than one that just waits out the antibiotic course.
Agreed: a short prednisone taper for the flare, clarithromycin continued unchanged for its remaining two days, and colchicine avoided rather than dose-adjusted. All three voices converged once the rheumatologist's alternative removed the need to choose between the antibiotic and the interaction risk.
Noted for his chart rather than argued over: colchicine should be reconsidered for any future flare only once he is off clarithromycin and, ideally, once his renal function is reassessed, since the interaction risk resolves once the antibiotic clears his system but his CKD does not.